The city of Kansas City, Kansas, currently has 19 active clinical trials seeking participants for Breast Cancer research studies.
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Recruiting
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observa... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/08/2024
Locations: University of Kansas Cancer Center, Kansas City, Kansas
Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma
Phase IIB Trial of Bazedoxifene Plus Conjugated Estrogens
Recruiting
Women at risk for development of breast cancer and experiencing vasomotor menopausal symptoms (hot flashes) will be randomized to bazedoxifene (BZA) plus conjugated estrogens (CE) for 6 months versus a wait list control. Two risk factors for development of breast cancer will be studied pre-study and after 6 months: fibroglandular volume (FGV) on mammogram as assessed by Volpara software and proliferation by Ki-67 immunocytochemistry in benign breast tissue acquired by random periareolar fine nee... Read More
Gender:
Female
Ages:
Between 45 years and 64 years
Trial Updated:
01/25/2024
Locations: University of Kansas Medical Center, Kansas City, Kansas
Conditions: Risk Reduction, Breast Cancer
Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC
Recruiting
This study will assess if the presence of immune system cells in and around the tumor impacts tumor shrinkage in patients receiving neoadjuvant chemoimmunotherapy for triple-negative breast cancer.
Gender:
Female
Ages:
Between 18 years and 70 years
Trial Updated:
12/05/2023
Locations: The University of Kansas Cancer Center - Main Hospital, Kansas City, Kansas +1 locations
Conditions: Triple Negative Breast Cancer, Breast Cancer
Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study
Recruiting
This phase III trial compares the effect of active symptom monitoring and patient education to patient education alone in helping young women with stage I-III breast cancer stay on their hormone therapy medicines. The patient education tool contains interactive weblinks which provide patients with education material about breast cancer and side effects of therapy. Symptom monitoring is a weblink via email or text message with questions asking about symptoms. Hormone therapy for breast cancer can... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
11/09/2023
Locations: University of Kansas Cancer Center, Kansas City, Kansas
Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Hormone Receptor-Positive Breast Carcinoma
Efficacy of Point Of Service Testing in MBC
Recruiting
This study will assess the efficacy of an innovative point of service cancer genetics counseling delivery model for metastatic breast cancer (MBC) patients whom have received a referral for hereditary cancer genetic counseling and testing.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/21/2023
Locations: The University of Kansas Cancer Center, Westwood Campus, Kansas City, Kansas
Conditions: Metastatic Cancer, Breast Cancer
Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry
Recruiting
PROGECT is a registry for patients with Triple Negative breast cancer (TNBC) or patients who have an identified germline mutations (such as a mutation on the BRCA1 or BRCA2 genes).
Gender:
All
Ages:
All
Trial Updated:
05/08/2023
Locations: KCCC West, Kansas City, Kansas
Conditions: Breast Cancer, Hereditary Breast and Ovarian Cancer
Protocol for Women at Increased Risk of Developing Breast Cancer
Recruiting
The overall goal of this project is to develop an integrative system of breast cancer risk assessment based on epidemiologic and biologic risk variables, as well as to develop or refine risk biomarkers which may be useful in predicting and monitoring response to prevention interventions.
Gender:
Female
Ages:
Between 30 years and 65 years
Trial Updated:
02/02/2023
Locations: University of Kansas Medical Center, Kansas City, Kansas
Conditions: Breast Cancer